WO2004104216A3 - Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) - Google Patents

Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) Download PDF

Info

Publication number
WO2004104216A3
WO2004104216A3 PCT/EP2004/005071 EP2004005071W WO2004104216A3 WO 2004104216 A3 WO2004104216 A3 WO 2004104216A3 EP 2004005071 W EP2004005071 W EP 2004005071W WO 2004104216 A3 WO2004104216 A3 WO 2004104216A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
dpp4
diseases
dipeptidylpeptidase
therapeutics
Prior art date
Application number
PCT/EP2004/005071
Other languages
English (en)
Other versions
WO2004104216A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Priority to EP04732310A priority Critical patent/EP1631680A2/fr
Publication of WO2004104216A2 publication Critical patent/WO2004104216A2/fr
Publication of WO2004104216A3 publication Critical patent/WO2004104216A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une dipeptidylpeptidase IV (DPP4) liée aux troubles cardio-vasculaires, dermatologiques, cancéreux, hématologiques, aux maladies respiratoires, gastro-intestinales et hépatiques, aux troubles urinaires et aux maladies du métabolisme. Cette invention a également trait à des dosages d'identification de composés utilisés dans le traitement ou la prévention de troubles cardio-vasculaires, dermatologiques, cancéreux, hématologiques, aux maladies respiratoires, gastro-intestinales et hépatiques, aux troubles urinaires et aux maladies du métabolisme. Ladite invention a également pour objet des composés qui se lient et/ou activent ou inhibent l'activité de DPP4, ainsi que des compositions pharmaceutiques contenant de tels composés.
PCT/EP2004/005071 2003-05-21 2004-05-12 Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) WO2004104216A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04732310A EP1631680A2 (fr) 2003-05-21 2004-05-12 Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011481.3 2003-05-21
EP03011481 2003-05-21

Publications (2)

Publication Number Publication Date
WO2004104216A2 WO2004104216A2 (fr) 2004-12-02
WO2004104216A3 true WO2004104216A3 (fr) 2005-03-03

Family

ID=33462083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005071 WO2004104216A2 (fr) 2003-05-21 2004-05-12 Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)

Country Status (2)

Country Link
EP (1) EP1631680A2 (fr)
WO (1) WO2004104216A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1741790A1 (fr) * 2005-03-24 2007-01-10 DIGILAB BioVisioN GmbH Methodés pour identifier et caractériser des prolyl oligopeptidases en utilisant leurs substrates et produits
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
KR101376471B1 (ko) * 2006-03-13 2014-03-27 백톤 디킨슨 앤드 컴퍼니 디펩티딜 펩티다제-관련 질병 상태의 진단 및 예후
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
JP6065172B2 (ja) * 2010-10-22 2017-01-25 国立大学法人名古屋大学 微小血管障害又はその関連疾患のバイオマーカー
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
MX2016009491A (es) * 2014-01-27 2017-01-13 Medimmune Llc Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.
MX2016015609A (es) 2014-05-30 2017-08-02 Regeneron Pharma Animales con dipeptidil peptidasa iv (dpp4) humanizada.
US10351630B2 (en) 2015-01-09 2019-07-16 Medimmune, Llc Assay to detect human DPP-4
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
AU2016349113A1 (en) * 2015-11-04 2018-06-07 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3606507A4 (fr) * 2017-04-03 2020-11-11 CDI Laboratories Inc. Biomarqueurs sérologiques pour le diagnostic précoce du cancer du poumon
EP3606527A1 (fr) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Agoniste de ppar-gamma pour le traitement de la paralysie supranucléaire progressive
CN115671109A (zh) * 2022-11-23 2023-02-03 辽宁康辰诺信医药科技有限公司 磷酸西格列汀的用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034538A2 (fr) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification de proteases serines, et leurs inhibiteurs synthetiques
EP0905240A1 (fr) * 1997-09-29 1999-03-31 Applied Research Systems Ars Holding N.V. Amino-terminale tronquée C-C chemokin et d'un antagoniste chemokin
WO1999046272A1 (fr) * 1998-03-09 1999-09-16 Fondatech Benelux N.V. Modulateurs de la serine peptidase
JP2000143699A (ja) * 1998-11-11 2000-05-26 Shionogi & Co Ltd 補体依存性細胞障害を抑制するモノクローナル抗体
WO2001074299A2 (fr) * 2000-04-01 2001-10-11 The Research Foundation Of State University Of New York Compositions et methodes permettant l'inhibition de la propagation du cancer et de l'angiogenese
WO2002053169A2 (fr) * 2001-01-02 2002-07-11 Keyneurotek Ag I.G. Utilisation d'inhibiteurs enzymatiques de la dipeptidylpeptidase iv (ec 3.4.14.5) ainsi que de l'aminopeptidase n (ec 3.4.11.2), seuls ou en combinaison, et preparations pharmaceutiques contenant ces inhibiteurs pour la prevention et / ou la therapie de processus et etats pathologiques neurodegeneratifs aigus et chroniques
CA2436724A1 (fr) * 2001-01-02 2002-07-11 Siegfried Ansorge Utilisation combinee d'inhibiteurs enzymatiques et de preparations pharmaceutiques constituees de ces inhibiteurs pour le traitement et la prophylaxie de l'arteriosclerose, pour le traitement et la prevention de reactions allergiques de type i selon la classification de gell et coombs et pour le traitement et la prevention
WO2003002596A2 (fr) * 2001-06-27 2003-01-09 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la dipeptidyl peptidase iv
WO2003015775A1 (fr) * 2001-08-17 2003-02-27 Probiodrug Ag Inhibiteurs de dipeptidyl peptidase iv et leurs utilisations pour diminuer la pression sanguine
WO2003017936A2 (fr) * 2001-08-23 2003-03-06 Yale University Utilisation d'inhibiteurs de la dppiv utilises comme agents diuretiques et anti-hypertenseurs

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034538A2 (fr) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification de proteases serines, et leurs inhibiteurs synthetiques
EP0905240A1 (fr) * 1997-09-29 1999-03-31 Applied Research Systems Ars Holding N.V. Amino-terminale tronquée C-C chemokin et d'un antagoniste chemokin
WO1999046272A1 (fr) * 1998-03-09 1999-09-16 Fondatech Benelux N.V. Modulateurs de la serine peptidase
JP2000143699A (ja) * 1998-11-11 2000-05-26 Shionogi & Co Ltd 補体依存性細胞障害を抑制するモノクローナル抗体
WO2001074299A2 (fr) * 2000-04-01 2001-10-11 The Research Foundation Of State University Of New York Compositions et methodes permettant l'inhibition de la propagation du cancer et de l'angiogenese
WO2002053169A2 (fr) * 2001-01-02 2002-07-11 Keyneurotek Ag I.G. Utilisation d'inhibiteurs enzymatiques de la dipeptidylpeptidase iv (ec 3.4.14.5) ainsi que de l'aminopeptidase n (ec 3.4.11.2), seuls ou en combinaison, et preparations pharmaceutiques contenant ces inhibiteurs pour la prevention et / ou la therapie de processus et etats pathologiques neurodegeneratifs aigus et chroniques
CA2436724A1 (fr) * 2001-01-02 2002-07-11 Siegfried Ansorge Utilisation combinee d'inhibiteurs enzymatiques et de preparations pharmaceutiques constituees de ces inhibiteurs pour le traitement et la prophylaxie de l'arteriosclerose, pour le traitement et la prevention de reactions allergiques de type i selon la classification de gell et coombs et pour le traitement et la prevention
WO2003002596A2 (fr) * 2001-06-27 2003-01-09 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la dipeptidyl peptidase iv
WO2003015775A1 (fr) * 2001-08-17 2003-02-27 Probiodrug Ag Inhibiteurs de dipeptidyl peptidase iv et leurs utilisations pour diminuer la pression sanguine
WO2003017936A2 (fr) * 2001-08-23 2003-03-06 Yale University Utilisation d'inhibiteurs de la dppiv utilises comme agents diuretiques et anti-hypertenseurs

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ABBOTT C A ET AL: "GENOMIC ORGANIZATION, EXACT LOCALIZATION, AND TISSUE EXPRESSION OF THE HUMAN CD26 (DIPEPTIDYL PEPTIDASE IV) GENE", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 5, 1994, pages 331 - 338, XP001026517, ISSN: 0093-7711 *
AICHI-GAKUIN JOURNAL OF DENTAL SCIENCE, vol. 19, no. 3, 1981, pages 70 - 83, ISSN: 0044-6912 *
COR ET VASA 1991 CZECHOSLOVAKIA, vol. 33, no. 3, 1991, pages 218 - 226, ISSN: 0010-8650 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1981, FUYAMADA H: "STUDIES ON CLINICAL BIOCHEMISTRY OF DI PEPTIDYL PEPTIDASE IV", XP002300854, Database accession no. PREV198375031295 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, ISHII NAOHITO ET AL: "Diagnostic significance of urinary enzymes for diabetes mellitus and hypertension", XP002300856, Database accession no. PREV199698602432 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1991, PAPIES B ET AL: "Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension", XP002300855, Database accession no. EMB-1991253987 *
DATABASE WPI Section Ch Week 200039, Derwent World Patents Index; Class B04, AN 2000-445041, XP002300857 *
ENZYME AND PROTEIN, vol. 48, no. 3, 1994, pages 174 - 182, ISSN: 1019-6773 *
HOSONO MITSUHARU ET AL: "Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction.", ATHEROSCLEROSIS, vol. 168, no. 1, May 2003 (2003-05-01), pages 73 - 80, XP002300852, ISSN: 0021-9150 *
LEFEBVRE JEAN ET AL: "Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema", HYPERTENSION (BALTIMORE), vol. 39, no. 2 Part 2, February 2002 (2002-02-01), pages 460 - 464, XP002300853, ISSN: 0194-911X *
NEUDECK HERMANN ET AL: "Histochemical evaluation of placental dipeptidyl peptidase IV (CD26) in pre-eclampsia: Enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational hypertensive disorders", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 37, no. 6, 1997, pages 449 - 458, XP008037065, ISSN: 1046-7408 *
See also references of EP1631680A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
WO2004104216A2 (fr) 2004-12-02
EP1631680A2 (fr) 2006-03-08

Similar Documents

Publication Publication Date Title
WO2004104216A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005114207A3 (fr) Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2005078117A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)
WO2005085466A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 2 associee a rho (rock2)
WO2004097358A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 2 transmembranaire humaine (tmprss2)
WO2005075662A3 (fr) Methodes diagnostiques et therapeutiques des maladies associees au kallikrein 2 (klk2)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005118840A3 (fr) Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10)
WO2005022164A3 (fr) Agents diagnostiques et agents therapeutiques destines a des maladies associees a la kallikreine 8 (klk8)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005090994A3 (fr) Diagnostic et therapeutique pour des maladies associees a la proteine kinase, dependante de cgmp, type 1 (prkg1)
WO2005083105A3 (fr) Diagnostic et traitement de maladies associees a la glycogene synthase kinase 3 beta (gsk3b)
WO2005095953A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 6 (ccr6)
WO2005085469A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 1 associee a rho (rock1)
WO2006013014A3 (fr) Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2004104595A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004732310

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004732310

Country of ref document: EP